3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
22.4.2025 18:00:00 CEST | Business Wire | Press release
3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/
3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the corporate market by combining wind, solar, and battery asset classes.
Vedrenne began his career in Europe at Gaz de France where he played a foundational role in the creation of Gasely, the trading business unit that evolved into Engie Global Markets, where he later became CEO. While running Engie’s natural gas midstream activities in Europe, he renegotiated the company’s long-term supply contracts to align them with markets, contributed to ensure European security of supply, and helped establish natural gas reverse flows to Ukraine in the wake of the Maidan uprisings and 2014 Russian-Ukrainian war. Before moving to the U.S. in 2021, Vedrenne led two significant projects for Engie: the development of renewable power purchase agreement (PPA) activities in Europe, and the net zero carbon project that defines Engie’s decarbonization ambition and trajectory to carbon neutrality by 2045.
“We are thrilled to welcome Philippe Vedrenne as the next CEO of 3Degrees,” said Dan Kalafatas, 3Degrees’ co-founder and Chair of the Board. “Our global search focused on selecting a new leader with the expertise to drive the next chapters of 3Degrees’ growth. Philippe brings a rare combination of global leadership experience, track record of success, service-leader orientation, and passion for bringing innovative decarbonization solutions to the world. The 3Degrees Board also wants to express deep gratitude to Steve McDougal. In his tenure as CEO, Steve spearheaded the company’s transformation from a small, North American-focused renewable energy commodity company into a leading global climate solutions provider advising some of the largest companies in the world.”
“I could not be more excited to assume the CEO role and help accelerate 3Degrees’ growth and our clients’ climate impact,” said Vedrenne. “The entire team is incredibly strong, with deep market and functional expertise. I’m looking forward to helping fuel the company’s continued expansion in both current and new markets, and to using our unique combination of market participation and client-centric focus to innovate new products and solutions. I’m honored to be asked to join such an exemplary organization, enabling me to work on a challenge of great urgency to us all.”
McDougal added, “Co-founding 3Degrees with Dan Kalafatas, and subsequently leading the company as CEO for the last ten years, has been one of the greatest privileges of my life. I am incredibly proud of what the 3Degrees team has built together over nearly two decades. I look forward to supporting the bright future for 3Degrees in my role on its Board of Directors and feel confident Philippe will be an excellent steward of the company as it expands its impact globally for our clients, partners, suppliers, employees, and the climate.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422978066/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom